Overexpression of the μ-opioid receptor in human non-small cell lung cancer promotes akt and mTOR activation, tumor growth, and metastasis

Anesthesiology

Volumn 116, Issue 4, 2012, Pages 857-867

  Lennon, Frances E ^a   Mirzapoiazova, Tamara ^a   Mambetsariev, Bolot ^a   Salgia, Ravi ^b   Moss, Jonathan ^b   Singleton, Patrick A ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALTREXONE; MAMMALIAN TARGET OF RAPAMYCIN; MU OPIATE RECEPTOR; NESTIN; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; TEMSIROLIMUS;

ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CARCINOMA CELL; CONTROLLED STUDY; EPIDEMIOLOGICAL DATA; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VIVO STUDY; LUNG ALVEOLUS CELL CARCINOMA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DISEASE PROGRESSION; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, OPIOID, MU; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859110859     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e31824babe2     Document Type: Article

References (71)

1. Bovill JG: Surgery for cancer: Does anesthesia matter? Anesth Analg 2010; 110:1524-6
2. Snyder GL, Greenberg S: Effect of anaesthetic technique and other perioperative factors on cancer recurrence. Br J Anaesth 2010; 105:106-15
3. Yeager MP, Rosenkranz KM: Cancer recurrence after surgery: A role for regional anesthesia? Reg Anesth Pain Med 2010; 35:483-4
4. Biki B, Mascha E, Moriarty DC, Fitzpatrick JM, Sessler DI, Buggy DJ: Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: A retrospective analysis. ANESTHESIOLOGY 2008; 109:180-7
5. Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E, Sessler DI: Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? ANESTHESIOLOGY 2006; 105:660-4 (Pubitemid 44477309)
6. Christopherson R, James KE, Tableman M, Marshall P, Johnson FE: Long-term survival after colon cancer surgery: A variation associated with choice of anesthesia. Anesth Analg 2008; 107:325-32
7. Myles PS, Peyton P, Silbert B, Hunt J, Rigg JR, Sessler DI: Perioperative epidural analgesia for major abdominal surgery for cancer and recurrence-free survival: Randomised trial. BMJ 2011; 342:d1491
8. Tavare AN, Perry NJ, Benzonana LL, Takata M, Ma D: Cancer recurrence after surgery: Direct and indirect effects of anesthetic agents*. Int J Cancer 2012; 130:1237-50
9. Afsharimani B, Cabot PJ, Parat MO: Morphine use in cancer surgery. Front Pharmacol 2011; 2:46
10. Afsharimani B, Cabot P, Parat MO: Morphine and tumor growth and metastasis. Cancer Metastasis Rev 2011; 30: 225-38
11. Mathew B, Lennon FE, Siegler J, Mirzapoiazova T, Mambetsariev N, Sammani S, Gerhold LM, LaRiviere PJ, Chen CT, Garcia JG, Salgia R, Moss J, Singleton PA: The novel role of the mu opioid receptor in lung cancer progression: A laboratory investigation. Anesth Analg 2011; 112:558-67
12. Gach K, Wyrebska A, Fichna J, Janecka A: The role of morphine in regulation of cancer cell growth. Naunyn Schmiedebergs Arch Pharmacol 2011; 384:221-30
13. Kasai S, Ikeda K: Pharmacogenomics of the human μ-opioid receptor. Pharmacogenomics 2011; 12:1305-20
14. Trescot AM, Datta S, Lee M, Hansen H: Opioid pharmacology. Pain Physician 2008; 11:S133-53 (Pubitemid 351682083)
15. Wei LN, Loh HH: Transcriptional and epigenetic regulation of opioid receptor genes: Present and future. Annu Rev Pharmacol Toxicol 2011; 51:75-97
16. Hwang CK, Kim CS, Kim do K, Law PY, Wei LN, Loh HH: Up-regulation of the mu-opioid receptor gene is mediated through chromatin remodeling and transcriptional factors in differentiated neuronal cells. Mol Pharmacol 2010; 78:58-68
17. Chen YL, Law PY, Loh HH: The other side of the opioid story: Modulation of cell growth and survival signaling. Curr Med Chem 2008; 15:772-8 (Pubitemid 351516793)
18. Martini L, Whistler JL: The role of mu opioid receptor desensitization and endocytosis in morphine tolerance and dependence. Curr Opin Neurobiol 2007; 17:556-64
19. Leo S, Nuydens R, Meert TF: Opioid-induced proliferation of vascular endothelial cells. J Pain Res 2009; 2:59-66
20. Dai X, Song HJ, Cui SG, Wang T, Liu Q, Wang R: The stimulative effects of endogenous opioids on endothelial cell proliferation, migration and angiogenesis in vitro. Eur J Pharmacol 2010; 628:42-50
21. Gupta K, Kshirsagar S, Chang L, Schwartz R, Law PY, Yee D, Hebbel RP: Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res 2002; 62:4491-8 (Pubitemid 34827313)
22. Zagon IS, McLaughlin PJ: Opioid antagonists inhibit the growth of metastatic murine neuroblastoma. Cancer Lett 1983; 21:89-94 (Pubitemid 14203088)
23. Singleton PA, Mambetsariev N, Lennon FE, Mathew B, Siegler JH, Moreno-Vinasco L, Salgia R, Moss J, Garcia JG: Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors. J Angiogenes Res 2010; 2:5
24. Singleton PA, Garcia JG, Moss J: Synergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesis. Mol Cancer Ther 2008; 7:1669-79
25. Singleton PA, Lingen MW, Fekete MJ, Garcia JG, Moss J: Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: Role of receptor transactivation. Microvasc Res 2006; 72:3-11 (Pubitemid 44118390)
26. Spiro SG, Tanner NT, Silvestri GA, Janes SM, Lim E, Vansteenkiste JF, Pirker R: Lung cancer: Progress in diagnosis, staging and therapy. Respirology 2010; 15:44-50
27. Stinchcombe TE, Bogart J, Veeramachaneni NK, Kratzke R, Govindan R: Annual review of advances in non-small cell lung cancer research: A report for the year 2010. J Thorac Oncol 2011; 6:1443-50
28. Tarantola M, Marel AK, Sunnick E, Adam H, Wegener J, Janshoff A: Dynamics of human cancer cell lines monitored by electrical and acoustic fluctuation analysis. Integr Biol (Camb) 2010; 2:139-50
29. Chen J, Ye L, Zhang L, Jiang WG: Placenta growth factor, PLGF, influences the motility of lung cancer cells, the role of Rho associated kinase, Rock1. J Cell Biochem 2008; 105: 313-20
30. Keese CR, Bhawe K, Wegener J, Giaever I. Real-time impedance assay to follow the invasive activities of metastatic cells in culture. Biotechniques 2002; 33:842-44, 846, 848-50
31. Hoffman RM, Yang M: Whole-body imaging with fluorescent proteins. Nat Protoc 2006; 1:1429-38
32. Maione P, Rossi A, Sacco PC, Bareschino MA, Schettino C, Gridelli C: Advances in chemotherapy in advanced nonsmall- cell lung cancer. Expert Opin Pharmacother 2010; 11: 2997-3007
33. Beland MD, Wasser EJ, Mayo-Smith WW, Dupuy DE: Primary non-small cell lung cancer: Review of frequency, location, and time of recurrence after radiofrequency ablation. Radiology 2010; 254:301-7
34. Xu J, Xu M, Hurd YL, Pasternak GW, Pan YX: Isolation and characterization of new exon 11-associated N-terminal splice variants of the human mu opioid receptor gene. J Neurochem 2009; 108:962-72
35. Onn A, Isobe T, Itasaka S, Wu W, O'Reilly MS, Ki Hong W, Fidler IJ, Herbst RS: Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. Clin Cancer Res2003; 9:5532-9 (Pubitemid 37499472)
36. Chen Y, Long H, Wu Z, Jiang X, Ma L: EGF transregulates opioid receptors through EGFR-mediated GRK2 phosphorylation and activation. Mol Biol Cell 2008; 19:2973-83
37. Belcheva MM, Tan Y, Heaton VM, Clark AL, Coscia CJ: Mu opioid transactivation and down-regulation of the epidermal growth factor receptor in astrocytes: Implications for mitogen- activated protein kinase signaling. Mol Pharmacol 2003; 64:1391-1401 (Pubitemid 37532229)
38. Fujioka N, Nguyen J, Chen C, Li Y, Pasrija T, Niehans G, Johnson KN, Gupta V, Kratzke RA, Gupta K: Morphine-induced epidermal growth factor pathway activation in nonsmall cell lung cancer. Anesth Analg 2011; 113:1353-64
39. Wu P, Hu YZ: Pi3K/akt/mTOR pathway inhibitors in cancer: A perspective on clinical progress. Curr Med Chem 2010; 17:4326-41
40. Chen JS, Wang Q, Fu XH, Huang XH, Chen XL, Cao LQ, Chen LZ, Tan HX, Li W, Bi J, Zhang LJ: Involvement of PI3k/PTEN/ AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatol Res 2009; 39:177-86
41. Zhao N, Guo Y, Zhang M, Lin L, Zheng Z: Akt-mTOR signaling is involved in Notch-1-mediated glioma cell survival and proliferation. Oncol Rep 2010; 23:1443-7
42. Malizzia LJ, Hsu A: Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma. Clin J Oncol Nurs 2008; 12:639-46
43. Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK, Testa JR: AKTand mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004; 23: 5853-7 (Pubitemid 39093031)
44. Arenberg D: Bronchioloalveolar carcinoma. Semin Respir Crit Care Med 2011; 32:52-61
45. Levy BP, Drilon A, Makarian L, Patel AA, Grossbard ML: Systemic approaches for multifocal bronchioloalveolar carcinoma: Is there an appropriate target? Oncology 2010; 24: 888-98, 900
46. Toonkel RL, Borczuk AC, Powell CA: Tgf-beta signaling pathway in lung adenocarcinoma invasion. J Thorac Oncol 2010; 5:153-7
47. Chen Z, Wang T, Luo H, Lai Y, Yang X, Li F, Lei Y, Su C, Zhang X, Lahn BT, Xiang AP: Expression of nestin in lymph node metastasis and lymphangiogenesis in non-small cell lung cancer patients. Hum Pathol 2010; 41:737-44
48. Janikova M, Skarda J, Dziechciarkova M, Radova L, Chmelova J, Krejci V, Sedlakova E, Zapletalova J, Langova K, Klein J, Grygarkova I, Kolek V: Identification of CD133+/nestin+ putative cancer stem cells in non-small cell lung cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2010; 154:321-26
49. Krupkova O Jr, Loja T, Zambo I, Veselska R: Nestin expression in human tumors and tumor cell lines. Neoplasma 2010; 57:291-98
50. Ryuge S, Sato Y, Wang GQ, Matsumoto T, Jiang SX, Katono K, Inoue H, Satoh Y, Masuda N: Prognostic significance of nestin expression in resected non-small cell lung cancer. Chest 2011; 139:862-9
51. Singleton PA, Moss J: Effect of perioperative opioids on cancer recurrence: A hypothesis. Future Oncol 2010; 6:1237-42
52. Zagon IS, McLaughlin PJ: Naltrexone modulates tumor response in mice with neuroblastoma. Science 1983; 221: 671-73 (Pubitemid 13026087)
53. Koo KL, Tejwani GA, Abou-Issa H: Relative efficacy of the opioid antagonist, naltrexone, on the initiation and promotion phases of rat mammary carcinogenesis. Anticancer Res 1996; 16:1893-8 (Pubitemid 26270700)
54. Farooqui M, Geng ZH, Stephenson EJ, Zaveri N, Yee D, Gupta K: Naloxone acts as an antagonist of estrogen receptor activity in MCF-7 cells. Mol Cancer Ther 2006; 5:611-20
55. Boehncke S, Hardt K, Schadendorf D, Henschler R, Boehncke WH, Duthey B: Endogenous-opioid peptides modulate immune response towards malignant melanoma. Exp Dermatol 2011; 20:24-8
56. Bhatia S, Thompson JA: Temsirolimus in patients with advanced renal cell carcinoma: An overview. Adv Ther 2009; 26:55-67
57. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global ARCC Trial: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-81 (Pubitemid 46849157)
58. Figlin RA: Mechanisms of disease: Survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC. Nat Clin Pract Oncol 2008; 5:601-9
59. Garcia JA, Danielpour D: Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther 2008; 7:1347-54
60. Faivre S, Kroemer G, Raymond E: Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006; 5:671-88 (Pubitemid 44151605)
61. Brachmann S, Fritsch C, Maira SM, Garca-Echeverra C: PI3K and mTOR inhibitors: A new generation of targeted anticancer agents. Curr Opin Cell Biol 2009; 21:194-8
62. Jacinto E, Loewith R, Schmidt A, Lin S, Regg MA, Hall A, Hall MN: Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6:1122-8 (Pubitemid 39468014)
63. Fasolo A, Sessa C: mTOR inhibitors in the treatment of cancer. Expert Opin Investig Drugs 2008; 17:1717-34
64. Abraham RT, Gibbons JJ: The mammalian target of rapamycin signaling pathway: Twists and turns in the road to cancer therapy. Clin Cancer Res 2007; 13:3109-14 (Pubitemid 46944891)
65. Manning BD, Cantley LC: AKT/PKB signaling: Navigating downstream. Cell 2007; 129:1261-74 (Pubitemid 46962095)
66. Frost RA, Lang CH: Protein kinase B/akt: A nexus of growth factor and cytokine signaling in determining muscle mass. J Appl Physiol 2007; 103:378-87 (Pubitemid 47092315)
67. Du K, Tsichlis PN: Regulation of the Akt kinase by interacting proteins. Oncogene 2005; 24:7401-09 (Pubitemid 41637980)
68. Donahue RN, McLaughlin PJ, Zagon IS: Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin. Exp Biol Med (Maywood) 2011; 236:883-95
69. Donahue RN, McLaughlin PJ, Zagon IS: The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice. Gynecol Oncol 2011; 122:382-8
70. Berkson BM, Rubin DM, Berkson AJ: Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: A report of 3 new cases. Integr Cancer Ther 2009; 8:416-22
71. Lissoni P, Malugani F, Malysheva O, Kozlov V, Laudon M, Conti A, Maestroni G: Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin- 2, melatonin and naltrexone: Modulation of interleukin- 2-induced antitumor immunity by blocking the opioid system. Neuro Endocrinol Lett 2002; 23:341-4 (Pubitemid 34987505)